LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Strona główna・Stock List・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Closed

SectorHealthcare

30.25 2.54

Buy Sell

Overview

Share price change

24h

Current

Min

29.27

Max

30.45

Key metrics
By Trading Economics
Income	-2.9M -66M
EPS	-0.84
Employees	316
EBITDA	-3.8M -77M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+82.08% upside

Dividends
By Dow Jones
Next Earnings	7 sie 2025

Market Stats
By TradingEconomics
Market Cap	-179M 2.7B
Previous open	27.71
Previous close	30.25

News Sentiment

By Acuity

51%

49%

314 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

34.81 / 38.24 Support & Resistance

Xenon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 maj 2025, 22:52 UTC

Earnings

Major Market Movers

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 maj 2025, 20:37 UTC

Top News

Earnings

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 maj 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 maj 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 maj 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 maj 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 maj 2025, 23:14 UTC

Top News

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 maj 2025, 22:46 UTC

Top News

Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 maj 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 maj 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 maj 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 maj 2025, 21:58 UTC

Earnings

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 maj 2025, 21:24 UTC

Earnings

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 maj 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 maj 2025, 20:54 UTC

Market Talk

Earnings

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 maj 2025, 20:54 UTC

Earnings

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 maj 2025, 20:51 UTC

Earnings

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 maj 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 maj 2025, 20:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 maj 2025, 20:50 UTC

Earnings

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 maj 2025, 20:26 UTC

Top News

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 maj 2025, 20:25 UTC

Earnings

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer Comparison

Price change

Xenon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

82.08% upside

12 Months Forecast

Average 54.15 USD 82.08%

High 65 USD

Low 42 USD

Based on 16 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to Xenon Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

34.81 / 38.24Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

314 / 382 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.